Mr. Shawn R Brandenburg, D.O. Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 4508 38th Street, Suite 133, Columbus, NE 68601 Phone: 402-562-4700 Fax: 402-562-4701 |
Dr. Dustin Lee Volkmer, M.D. Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 4508 38th St, Suite 133, Columbus, NE 68601 Phone: 402-562-4700 Fax: 402-562-4701 |
Michael H. Mcguire, M.D. Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 4508 38th Street, Suite 133, Columbus, NE 68601 Phone: 402-563-3644 Fax: 402-564-5805 |
Dr. Richard R. Cimpl, M.D. Orthopaedic Surgery Medicare: Medicare Enrolled Practice Location: 4508 38th St, Suite 133, Columbus, NE 68601 Phone: 402-563-3644 Fax: 402-564-5805 |
Mikayla Kelley, PA Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 4508 38th St Ste 133, Columbus, NE 68601 Phone: 402-562-4700 |
Dr. Ian D Crabb, MD Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 4508 38th St, Suite 133, Columbus, NE 68601 Phone: 402-562-4700 Fax: 402-562-4701 |
News Archive
Bariatric surgeries, such as a gastric bypass, are currently the most effective anti-obesity therapies. They also lead to a reduced insulin resistance. However, the pitfall of these surgical interventions is that they are highly invasive and often permanent procedures.
In a study that included long-term follow-up of obese patients with type 2 diabetes, bariatric surgery was associated with more frequent diabetes remission and fewer complications than patients who received usual care, according to a study in the June 11 issue of JAMA, a diabetes theme issue.
A new non-surgical, tissue-preserving therapeutic procedure is being developed to more effectively remove HPV infection and treat precursors of cervical cancer.
Intellect Neurosciences, Inc. a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has locked the database of the Company's Phase 1b clinical trial for its lead Alzheimer's candidate, OXIGON™ (OX1).
A study led by St. Jude Children's Research Hospital has discovered mutations in two genes that lead to the death of nerve cells in amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, and related degenerative diseases.
› Verified 8 days ago